argenx's Vyvgart Hytrulo Hits Phase 3 Primary Endpoint in Autoimmune Myositis

argenx (NASDAQ: ARGX) reported positive topline results from ALKIVIA, the Phase 3 trial of its subcutaneous FcRn blocker VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. The stock closed at $1,038.12 on August 20, up about 22% from $851.29 on August 14, the session before the August 17 readout.

The trial met its primary endpoint, with patients on efgartigimod showing a 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo (47.95 vs 32.56, p=0.0011). Treatment benefit appeared by Week 4 and was sustained through the full year, even as patients tapered corticosteroids.

The win held in the immune-mediated necrotizing myopathy (IMNM) subtype, where efgartigimod delivered a 14.8-point improvement over placebo (45.05 vs 30.24, p=0.0048). In dermatomyositis (DM), the 14.5-point improvement (51.51 vs 36.96) was clinically meaningful but did not reach statistical significance in the smaller cohort (p=0.1093). Efgartigimod was well tolerated, with a safety profile consistent with prior studies.

Why It Matters

Autoimmune myositis affects roughly 100,000 people in the U.S., about 20,000 of them with IMNM, a subtype with no approved therapy. The standard of care has been corticosteroids and broad immunosuppressants, which carry serious cumulative toxicity. ALKIVIA is the first Phase 3 study to show a statistically significant and clinically meaningful improvement in IMNM disease activity.

For argenx, the readout extends the VYVGART franchise beyond its two approved indications, generalized myasthenia gravis and CIDP, into a third autoimmune disease. The same FcRn mechanism that drives VYVGART also underpins argenx’s pipeline in Sjögren’s disease and systemic sclerosis. Our primer on the FcRn inhibitor mechanism explains why this class keeps producing readouts across indications.

The result lands a month after argenx agreed to acquire Forte Biosciences for about $2.2 billion, its push into vitiligo. The myositis win reinforces the immunology platform thesis that runs through both moves.

What Happens Next

argenx said detailed results will be presented at an upcoming medical meeting and that it plans to discuss the data with regulators. The ALKIVIA study enrolled 264 patients in a combined Phase 2/3 design, with 175 patients in the Phase 3 portion. The next catalysts are the full data presentation and a potential regulatory submission in myositis.

What It Means for the Trade

The 22% five-session move into the readout tells you the market was already pricing a win — argenx has trained investors to expect FcRn mechanism delivery across indications, and ALKIVIA is the third consecutive confirmation (gMG 2021, CIDP 2023, now myositis). The trade-relevant question is what’s left to re-rate from here, and the answer sits in label economics rather than the topline.

IMNM is the money indication inside this trial: ~20,000 U.S. patients with zero approved therapies, meaning first-mover exclusivity in a niche that has historically been treated with brutal corticosteroid-plus-IVIG regimens. The 14.8-point TIS separation with p=0.0048 in that cohort is a registrable number. Dermatomyositis’s 14.5-point effect missing significance (p=0.1093) in the smaller cohort is more nuanced: the point estimate is nearly identical to IMNM’s, which reads as a power problem rather than a biology problem — but the FDA approves on statistics, not point estimates, so expect the initial label (if filed this way) to anchor on IMNM, with DM either requiring the pooled/bigger picture or a supplementary filing. J&J’s nipocalimab and Imperial College’s trials are also circling myositis, so time-to-first-approval matters for the IMNM exclusivity window. For the deeper ARGX myositis analysis - what the $12B reaction actually bought and why IMNM, not DM, is the asset - start there.

What this does to the argenx model: VYVGART is approaching the plateau of its two launched indications, and the bull case from here is label stacking — myositis, plus the earlier-stage Sjögren’s and systemic sclerosis programs, plus the Forte Biosciences vitiligo entry. Each indication at argenx’s penetration curves has historically added $500 million-plus to peak sales. Myositis as the third pillar extends the franchise’s growth runway into the late 2020s, which is exactly what a stock trading at these levels (a $1,000-plus share price, premium multiple on ~$3 billion-plus in revenue) needs to hold its multiple.

Mechanism Context: Why FcRn Keeps Working in Myositis

The pattern across ALKIVIA and every other FcRn readout is worth internalizing as an investment framework. FcRn blockade lowers pathogenic IgG (the autoantibodies driving disease) without touching B cells, T cells, or the broader immune repertoire — so it delivers immunosuppression-free disease control. In myositis, the pathogenic logic is cleanest in IMNM, where anti-SRP and anti-HMGCR IgG autoantibodies drive complement-mediated muscle fiber necrosis; strip the IgG and the necrotic cascade quiets. The 47.95 mean TIS on treatment with benefit visible by Week 4 matches the fast-onset signature VYVGART shows in gMG and CIDP.

The competitive frame: IVIG (the incumbent crude version of the same mechanism — pooled IgG that saturates FcRn) is effective but monthly, infusion-heavy, supply-constrained, and running into chronic shortages. A subcutaneous weekly self-administered FcRn blocker that beats the IVIG-era standard while tapering steroids is a payer’s dream and a patient’s dream simultaneously. That substitution story is why argenx keeps converting trials into durable franchises rather than marginal wins.

Risks and What Could Go Wrong

The dermatomyositis statistics are the main near-term haircut risk: if regulators or payers read ALKIVIA as “IMNM-proven, DM-inconclusive,” the addressable population shrinks toward the 20,000-patient IMNM core, and the DM opportunity waits for either pooled analyses or a dedicated trial — a 2-3 year delay on that slice. Second, execution risk in commercial sequencing: myositis is managed by a scattered rheumatology/neurology mix with no established biologic pathway, so penetration depends on argenx building diagnostic awareness (autoantibody subtyping) before prescribing follows. Third, valuation risk: at $1,038 and a premium multiple, argenx prices in continued flawless execution — a stumble in Sjögren’s or systemic sclerosis, or a Forte integration hiccup, derates the whole label-stacking narrative. And fourth, competition creep: J&J’s nipocalimab is behind in myositis but ahead in other autoantibody indications; a head-to-head FcRn war across the autoimmune periphery would compress pricing power for everyone in the class.

None of these break the thesis; they size it. The myositis win keeps argenx on the trajectory it has been on since 2021 — mechanism validated, label count growing, and the next readout (Sjögren’s) now the marker to watch.